ScholarWorks@SUNGKYUNKWAN UNIVERSITY: LEE, JEONG EON

Detailed Information

LEE, JEONG EON (이정언)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Breast neoplasms:59||Breast cancer:45||Prognosis:24||breast cancer:22||Breast neoplasm:13||BRCA1:13||Breast:12||Neoadjuvant chemotherapy:10||BRCA2:10||Triplenegative breast cancer:10||Recurrence:9||Sentinel lymph node biopsy:9||Immunohistochemistry:9||Chemotherapy:8||MMP9:8||HER2:7||Survival:7||Estrogen receptor:6||neoadjuvant chemotherapy:6||Silibinin:6||Berberine:6||survival:5||Lymphatic metastasis:5||Cell invasion:5||EGFR:5||triplenegative breast cancer:5||Magnetic resonance imaging:5||Quality of life:5||breast neoplasm:5||Breast reconstruction:4||triple negative breast cancer:4||Metastasis:4||Nomograms:4||Mastectomy:4||Breast Neoplasms:4||Axilla:4||Tamoxifen resistance:4||Sentinel lymph node:4||Radiotherapy:3||Genes:3||BRCA mutation:3||Incidence:3||Treatment:3||magnetic resonance imaging:3||Treatment outcome:3||Mutation:3||HER2positive breast cancer:3||Korea:3||Neoadjuvant Therapy:3||Neoadjuvant therapy:3||Ductal carcinoma in situ:3||breast:3||radiotherapy:3||recurrence:3||Fibronectin:3||Breast Cancer:3||silibinin:3||Lymph node excision:3||Lymph nodes:3||Hormone receptor:3||Cancer survivors:3||Human epidermal growth factor receptor 2:3||Male:3||Validation:2||plateletderived growth factor receptor &:2||Mortality:2||Emigrants and immigrants:2||poor prognosis:2||Neoadjuvant treatment:2||MMP1:2||Neoplasm metastasis:2||CD44:2||Health behavior:2||Neoplasms:2||Health knowledge:2||MMP2:2||progesterone receptor:2||prognosis:2||Liver cirrhosis:2||Intrinsic subtype:2||Nipplesparing mastectomy:2||propensity score:2||Lobular carcinoma:2||metastatic breast cancer:2||quality of life:2||breast neoplasms:2||BRCA2 gene mutation:2||radiomics:2||Carcinoma:2||Subcutaneous mastectomy:2||Nomogram:2||Cell migration:2||residual cancer burden:2||STAT3:2||casecontrol study:2||Depression:2||Local recurrence:2||#946:2||Triple negative breast neoplasms:2||Hepatocellular carcinoma:2||chemotherapy:2||MRI:2||Hereditary:2||Oncotype DX:2||zerumbone:2||Segmental mastectomy:2||Lymph node:2||hormone receptor:2||Hereditary breast:2||TGFbeta 1:2||Prognostic factor:2||Goserelin:2||mammography:2||Hereditary breast and ovarian cancer syndrome:2||lymph nodes:2||Hereditary breast cancer:2||Tamoxifen:2||Silybum marianum:2||Follicular lymphoma:2||Mass screening:2||ErbB2:2||epidermal growth factor receptor:2||Breast cancer survivors:2||Epidemiology:2||Aged:2||Adjuvant chemotherapy:2||Radiation therapy:2||Xenograft:2||Body image:2||Young breast cancer:2||Young women:2||Zerumbone:2||IL8:2||Endocrine therapy:2||Axillary lymph node dissection:2||Ki67:2||<:2||p53:2||Korean:2||Neoadjuvant:2||Anxiety:2||#945:2||Fat necrosis:1||Feasibility:1||Female:1||Fertility:1||Fibronectins:1||Financial stress:1||Follicular neoplasm:1||Follicular thyroid carcinoma:1||Founder variant:1||Founders:1||Frozen section analysis:1||Frozen sections:1||Gamma cameras:1||Gamma probe:1||Ganglioneuroma:1||GenesWell BCT assay:1||GenesWell BCT score:1||Genetic counseling:1||Genetic predisposition:1||Genetic testing:1||Genomics:1||GnRH:1||Gonadotropinreleasing hormone:1||Gonadotropinreleasing hormone agonist:1||Granulomatous mastitis:1||HBC:1||HBV:1||HER2:1||HER2 positivity:1||HER2 protein:1||HER2+ breast cancer:1||HER2overexpressing breast cancer:1||HER2positive (HR/HER2+) breast cancer:1||HER2/neu discordance:1||HER3:1||HLADR Antigens:1||HR+/HER2early breast cancer:1||Healthrelated quality of life (HRQoL):1||Healthcare providers:1||Hematology/Oncology:1||Hematology/Oncology General:1||Her2:1||Hereditary breast cancer syndrome:1||Hereditary breast neoplasm:1||Hereditary cancer:1||Hereditary neoplastic syndromes:1||Heterozygot:1||Hormone receptor negative:1||Hormone receptorpositive breast cancer:1||Human:1||IL1:1||IL1 beta:1||IL1β IL8:1||IL6:1||Ileum:1||Immune gene signature:1||Immune responserelated genes (igenes):1||Immunohistoch:1||Incidence rate:1||Incidental findings:1||Indocyanine green:1||Inflammation:1||Insurance:1||Integrin:1||Intervention:1||Intracystic papillary carcinoma:1||Intramammary lymph node:1||Invasion:1||Invasive:1||Invasive ductal breast cancer:1||Invasive ductal carcinoma:1||Ipsilateral breast cancer recurrence:1||Ischaemic time:1||Isoflavones:1||JAKs:1||Korean women:1||LDL cholesterol:1||Laparoscopy:1||Latissimus dorsi flap (LD flap):1||Letrozole:1||Local Recurrence:1||Local neoplasm recurrence:1||Localization:1||Locoregional neoplasm recurrence:1||Locoregional therapy:1||Lymph Node Excision:1||Lymph no:1||Lymph node ratio:1||Lymphatic Metastasis:1||Lymphedema:1||Lymphoscintigraphy:1||Lymphovascular invasion:1||Lysosome:1||MCF7 human breast cancer cells:1||MEK:1||MEK/ERK pathway:1||MEK/ERK signaling pathway:1||MIB1:1||MMP3:1||Machine learning:1||Male breast cancer:1||Malignant melanoma:1||Mammaplasty:1||Mammographic density:1||Mammography:1||Manganese:1||Margins of Excision:1||Margins of excision:1||Marital status:1||Mastectomy, Segmental:1||Matrix metalloproteinase9 (MMP9):1||Medullary carcinoma:1||Menopausal status:1||Methylation:1||Methylene blue:1||Methylene blue dye:1||Microcalcification:1||Missense mutation:1||Mitogenactivated protein kinase kinase:1||Molecular diagnostic techniques:1||Molecular subtype:1||Molecular subtypes:1||Molybdenum:1||Mucinous:1||Mucinous cystadenocarcinoma:1||Musclesparing la:1||Myelolipoma:1||Myriad II:1||N3:1||NBS1:1||NFB:1||NFkappa B:1||Neoadjuvant TCHP regimen:1||Neoplasm metastasi:1||Neoplasm recurrence:1||Neoplasm staging:1||Nerve growth factor:1||Neural:1||No:1||NodePositive Breast Cancer:1||OCR:1||Obesity:1||Objective measured:1||Obstetrics/Gynecology:1||Obstetrics/Gynecology General:1||Oligometastases:1||Oncology:1||Ovarian cancer syndrome:1||Ovarian neoplasm:1||Ovarian neoplasms:1||Ovarian protection:1||Ovarian suppression:1||Overall survival:1||PAM50:1||PDGFCC:1||PDGFRA:1||PET CT:1||PI3K:1||PKCalpha:1||PSCAD/EMTDC:1||Paget disease:1||Pathologic complete response:1||Patientreported outcome (PRO):1||Penetrance of BRCA mutation:1||Perioperative period:1||Phyllodes tumor:1||Physical activity:1||Pifithrinalpha:1||Poor prognosis:1||Population characteristics:1||Port insertion site recurrence:1||Postmastectomy radiation therapy:1||Postoperative period:1||Prediction:1||Prediction mod:1||Pregnancy:1||Pregnancy desire:1||Pregnancy rate:1||Premenopausal:1||Premenopausal women:1||Preoperative imaging:1||Prevalence:1||Prevention:1||Primary systemic therapy:1||Professional education:1||Progesterone receptor:1||Progesterone receptors:1||Progn:1||Prognostic biomarker:1||Prognostic factors:1||Prognostic markers:1||Prognostic model:1||Program development:1||Program evaluation:1||Proliferationrelated genes (pgenes):1||Prophylactic mastectomy:1||Proportion:1||Proteasome:1||Psychosocial support:1||Pure mucinous adenocarcinoma:1||QoL:1||Radioisotope:1||Radiologic complete response:1||Radiotherapy Recurren:1||Randomized controlled trials:1||Rare benign adrenal tumor:1||Ratio:1||Real world evidence:1||Receptor:1||Reconstruction methods:1||Regional:1||Relapse pattern:1||Relapsefree survival:1||Reliability:1||Res:1||Response:1||Return to work:1||Risk:1||Risk factors:1||Risk of distant metastasis:1||Rosuvastatin:1||SATSF:1||SKBR3 cells:1||STAT3:1||STAT1:1||Salpingooophorectomy:1||Salpingoovariectomy:1||Schwannoma:1||Scott transformer:1||Screendetected:1||Second primary:1||Secondary partial mastectomy:1||Segmental:1||Selfmanagement:1||Sensitivity:1||Sentine:1||Sentinel Lymph Node Biopsy:1||Sentinel lymph node biopy:1||Serial body weight change:1||Short form development:1||Skeletal muscle index:1||Skinsparing mastectomy:1||Smad3:1||Somatoform disorders:1||Sonography:1||Soy:1||Src:1||Stigma:1||Strategy:1||Stroke:1||Subcutaneous Mastectomy:1||Surgery:1||Surgical staplers:1||Surgical wound infection:1||Survival outcome:1||Survivorship:1||Systemic therapy:1||TCHP:1||TGFbeta:1||TGFbeta 2:1||TGFα:1||TNBC:1||TNFalpha:1||TNM stage:1||TNM staging:1||TP53:1||TPA:1||TWIST1:1||Target goal:1||Taxane:1||Technetium 99m Sestamibi:1||Trace elements:1||Transcription factor AP1:1||Treatment interruption:1||Triple negative:1||Triple negative breast cancer:1||Triple negative breast cancer (TNBC):1||Triplenegative Breast Neoplasms:1||Triplenegative breast neoplasms:1||Tubular:1||Tumor burden:1||Tumor suppressor protein p53:1||Tumorinfiltrating lymphocytes:1||Ultrasonography:1||Ultrasound:1||VEGF:1||Validation study:1||Vascular endothelial growth factor (VEGF):1||Visceral adipose tissue area:1||Volumetry:1||WNT5A:1||Young adult:1||adjuvant endocrine therapy:1||algorithm:1||altered appearance distress:1||anchorageindependent growth:1||angiosarcoma:1||axilla:1||axillary lymph node dissection:1||b:1||basallike breast cancer:1||benign breast disease:1||berberine:1||biomarker:1||bladder cancer:1||bleeding:1||body
image:1||bone metastasis:1||brain metastasis:1||brca1:1||brca2:1||breast angiosarcoma:1||breast cancer survivor:1||breast conserving surgery:1||c.5339T >:1||calcitriol:1||cancer:1||cancer survivor:1||celastrol:1||cell cycle arrest:1||cell invasion:1||central neck dissection:1||cfDNA:1||cholecalciferol:1||cholesterol:1||circadian rhythm:1||circulating tumor DNA:1||clips:1||concordance:1||conditional survival:1||develop:1||diagnosis:1||diagnostic value:1||disease free survival:1||diseasefree survival:1||drug monitoring:1||early breast cancer:1||endocrine symptoms:1||endocrine therapy:1||epidemiology:1||estrogen receptor:1||estrogen receptor&:1||excision:1||exosomes:1||expression assay:1||extracellular vesicles:1||fibronectin:1||gastric cancer:1||gene:1||genotype:1||happiness:1||hereditary breast and ovarian cancer syndrome:1||heregulinb:1||heterogeneity:1||histone deacetylase 11:1||hope:1||hormone receptorpositive breast cancer:1||hormone replacement therapy:1||human:1||human epidermal growth factor receptor 2:1||hypermethylation:1||indocyanine green:1||indocyanine green (ICG):1||interleukin 1&:1||interleukin 8:1||invasive ductal carcinoma:1||kinetics:1||knowledge:1||late distant recurrence:1||lipids:1||liver cancer:1||local:1||localization:1||luminal A breast cancer:1||lung metastasis:1||lymphocytes:1||machine learning:1||macrophages:1||matrix metalloproteinase 1:1||matrix metalloproteinase 9:1||mechanism:1||menopause:1||metabolic syndrome:1||metabolite:1||metachronous second primary neoplasm:1||metaplastic breast cancer:1||metastases:1||metastasis:1||microfluidic chip:1||model:1||molecular subtypes:1||mutation:1||nCounter mRNA expression assay:1||neoadjuvant chemotherapy:1||neoadjuvant chemotherapy (NAC):1||neoadjvant chemotherapy:1||neoplasm:1||neoplasms, multiple primary:1||nodepositive breast cancer:1||nonpalpable:1||nuclear protein 1:1||number of lymph nodes:1||oncology:1||oncotype DX recurrence score:1||oral calcium:1||ovarian cancer syndrome:1||p.Leu1780Pro:1||p16:1||p21:1||pathologic complete response:1||pathologic complete response (pCR):1||patientreported outcome:1||perfusion:1||phorbol ester:1||plateletderived growth factorBB:1||polyaneuploid cancer cells:1||predict:1||prediction model:1||predictive value:1||pregnancy:1||premenopausal:1||premenopausal patients:1||primary angiosarcoma of the breast:1||primary sarcoma:1||prognostic biomarker:1||prognostic factor:1||prognostic value:1||prospective cohort:1||purpose in life:1||radiationinduced dermatitis:1||radical cystectomy:1||reentry period:1||refractory:1||residual proliferative cancer burden:1||resistance:1||risk classification:1||risk factor:1||routine followup:1||screening:1||second primary cancer:1||secondary:1||segmental:1||selection bias:1||sentinel lymph node localization:1||skin toxicity:1||socioeconomic status:1||stage IV breast cancer:1||stanniocalcin1:1||surgery:1||surveillance:1||survivor:1||survivorship:1||tamoxifen:1||tamoxifenresistant breast cancer:1||thyroid cancer:1||total thyroidectomy:1||trajectory:1||trastuzumab resistance:1||triple negative breast neoplasm:1||triplenegative breast neoplasm:1||tumor response:1||tumorInfiltrating:1||tumorassociated macrophage:1||ultrasonography:1||unknown primary:1||urethral recurrence:1||variant of uncertain significance:1||variation:1||vascular endothelial growth factor A:1||vitamin:1||young breast cancer patients:1||ΑSMA:1||골수지방종:1||부신 희귀 양성종양:1||부신낭종:1||신경수초종:1||신경절신경종:1||(+) breast cance:1||12Otetradecanoyl phorbol13acetate (TPA):1||= 1 cm Invasive breast cancer:1||= 1 cm i:1||A proliferationinducing ligand:1||ABO blood type:1||ACTA2:1||AJCC 8th edition:1||AKT:1||ALDH:1||AP1:1||AREG:1||ASCO/CAP guidelines:1||Absorbable implants:1||Adenocarcinoma:1||Adjuvant radiotherapy:1||Adjuvant treatment:1||Adrenal cyst:1||Akt:1||Akt pathway:1||Alopecia:1||Altered appearance:1||AmpliSeq:1||AntiHER2 targeted therapy:1||Anticipation:1||Appearance:1||Artificial intelligence:1||Asia:1||Asian population:1||At feeding system:1||Axillary:1||Axillary arch:1||Axillary lymph node:1||Axillary lymph node dissections:1||Axillary pathologic complete response:1||BCT score:1||BRCA:1||BRCA 1/2:1||BRCA genes:1||BRCA1 gene:1||BRCA1 genes:1||BRCA2 gene:1||BRCA2 genes:1||BRCAPRO:1||BRCAmutation:1||BRIP1:1||Background parenchymal enhancement:1||Bilateral mastectomy:1||Biology:1||Bmi1:1||Body mass index:1||Bone:1||Bre:1||Breast Neoplasm:1||Breast Reconstruction:1||Breast cancer metastasis:1||Breast cancer surgery:1||Breast cancer survivor:1||Breast conserving surgery:1||Breast neoplams:1||C:1||CC chemokine receptor type 2:1||CXC motif chemokine ligand 13:1||CCL2:1||CD163 protein:1||CMT:1||CSIHC4:1||CTGF:1||CTS5:1||CXCL8:1||Cancer:1||Cancer survivor guidelines:1||Carcinoma, Intraductal, Noninfiltrating:1||Cardiotoxicity:1||Cdc2:1||Celastrol:1||Cell adhesion:1||Cell cycle regulator:1||Change:1||Chemokine (CC motif) ligand 2:1||Chemotherapyinduced skin change:1||Childbirth:1||Clinical outcome:1||Clinical practice patterns:1||Cohort:1||Combined mo:1||Complete Response:1||Complete response:1||Complications of Pregnancy:1||Computed Tomography:1||Computed tomography:1||Contralateral sentinel lymph node biopsy:1||Core needle biopsy Estrogen receptors:1||Cosmetic:1||Costs and cost analysis:1||Cyclin B1:1||Cyclooxygenase2:1||Cyr61:1||CytologyProven:1||Cytologyproven axillary metastasis:1||DIEP flap:1||DNA methylation:1||Deep inferior epigas:1||Dermal:1||Differential:1||Differentiated thyroid cancer (DTC):1||Diffuse large Bcell lymphoma:1||Diseasefree survival:1||Distress:1||Divorce:1||Double heterozygosity:1||Drug therapy:1||Dryness:1||Dullness:1||Dyslipidemia:1||EGF:1||ER status:1||ERhigh:1||ERlow:1||ERK:1||Early failure:1||Education:1||Employment:1||Endoscopic thyroidectomy:1||Entelon:1||Epithelialmesenchymal transition:1||Equivocal:1||ErbB2 receptor:1||Estrogen receptors:1||Ethnic groups:1||Excisio:1||Exosomes:1||Extracellular signalregulated kinase:1||Extracellular vesicles:1||Ezetimibe:1||FDG PET:1||FISH:1||Familial:1||Familial breast cancer:1||Familial cancer:1||Family history:1||

STATISTICS: Total View :0; Today View :2,617

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE